Trial Profile

A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brilacidin (Primary)
Indications COVID-19 respiratory infection
Focus Therapeutic Use
Sponsors Innovation Pharmaceuticals

Most Recent Events

07 Mar 2022 Results presented in an Innovation Pharmaceuticals Media Release.
25 Oct 2021 According to an Innovation Pharmaceuticals media release, the company anticipates reporting topline results from this trial in the week of November 8th .
13 Aug 2021 According to an Innovation Pharmaceuticals media release, topline results from this trial are anticipated to be available one week after database lock, with full analysis to follow.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com